Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-01. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
The authors also performed regression analyses to demonstrate the relationship between tooth height and skull length, and found that varanids like the crocodile monitor had substantially greater ratios of tooth height to skull length than those of Tyrannosaurus, indicating that the teeth of theropods were not too big to be covered by extraoral tissues when the mouth was closed.
Diagnosis is typically based on medical imaging, such as plain X-rays, and symptoms. In severe OI, signs on medical imaging include abnormalities in all extremities and the spine. As X-rays are often insensitive to the comparatively smaller bone density loss associated with type I OI, DEXA scans may be needed. An OI diagnosis can be confirmed through DNA or collagen protein analysis, but in many cases, the occurrence of bone fractures with little trauma and the presence of other clinical features such as blue sclerae are sufficient for a diagnosis. A skin biopsy can be performed to determine the structure and quantity of type I collagen. While DNA testing can confirm the diagnosis, it cannot absolutely exclude it because not all mutations causing OI are yet known and/or tested for. OI type II is often diagnosed by ultrasound during pregnancy, where already multiple fractures and other characteristic features may be visible. Relative to control, OI cortical bone shows increased porosity, canal diameter, and connectivity in micro-computed tomography. OI can also be detected before birth by using an in vitro genetic testing technique such as amniocentesis.
== Natural occurrence == Accurate measurements, beginning in the early 1970s, appeared to detect primordial plutonium-244, making it the shortest-lived primordial nuclide. As the age of the Earth is about 56 half-lives of 244Pu, the amount of 244Pu left should be very small; Hoffman et al. estimated its content in the rare-earth mineral bastnasite as c244 = 1.0×10−18 g/g, which corresponded to the content in the Earth crust as low as 3×10−25 g/g (i.e. the total mass of plutonium-244 in Earth's crust is about 9 g). Since 244Pu cannot be easily produced by natural neutron capture in the low neutron activity environment of uranium ores (see below), its presence cannot plausibly be explained by any other means than creation by r-process nucleosynthesis in supernovae or neutron star mergers. However, the detection of primordial 244Pu in 1971 is not confirmed by recent, more sensitive measurements using accelerator mass spectrometry. In a 2012 study, no traces of 244Pu in the samples of bastnasite (taken from the same mine as in the early study) were observed, so only an upper limit on the 244Pu content was obtained: c244 < 1.5×10−19 g/g: 370 (or fewer) atoms per gram of the sample, at least seven times lower than the abundance measured by Hoffman et al. A 2022 study, once again using accelerator mass spectrometry, could not detect 244Pu in Bayan Obo bastnasite, finding an upper limit of < 2.1×10−20 g/g (about seven times lower than the 2012 study). Thus, the 1971 detection cannot have been a signal of primordial 244Pu.
Blood factors (Factor VIII and Factor IX) Thrombolytic agents (tissue plasminogen activator) Hormones (insulin, glucagon, growth hormone, gonadotrophins) Haematopoietic growth factors (Erythropoietin, colony-stimulating factors) Interferons (Interferons-α, -β, -γ) Interleukin-based products (Interleukin-2) Vaccines (Hepatitis B surface antigen) Monoclonal antibodies (Various) Additional products (tumour necrosis factor, therapeutic enzymes) Research and development investment in new medicines by the biopharmaceutical industry stood at $65.2 billion in 2008. A few examples of biologics made with recombinant DNA technology include:
Sources: en.wikipedia.org
Examples of unsaturated fatty acids are palmitoleic acid, oleic acid, myristoleic acid, linoleic acid, and arachidonic acid. Foods containing unsaturated fats include avocado, nuts, olive oil, and vegetable oils, such as canola. Meat products contain both saturated and unsaturated fats. The amount of unsaturated fat consumed should be in a range of about 20-35% of one's daily caloric intake. Most foods contain both unsaturated and saturated fats.
=== DNA damage and cellular stress === CK1δ can be also activated by genotoxic stress and DNA damage in a p53-dependent manner, and phosphorylate key regulatory proteins in response to these processes. CK1δ phosphorylates human p53 on Ser-6, Ser-9, and Ser-20. Moreover, CK1δ phosphorylates p53 on Thr-18, once p53 is already phospho-primed, permitting a lower p53-Mdm2 binding and higher p53 activity. Under normal conditions, CK1δ can phosphorylate Mdm2 on Ser-240, Ser-242, Ser-246, and Ser-383, permitting higher p53-Mdm2 stability and further p53 degradation. On the contrary, after DNA damage, ATM phosphorylates CK1δ, which can subsequently phosphorylate Mdm2 inducing its proteasomal degradation. Under hypoxia, CK1δ is involved in reducing cell proliferation by interfering with HIF-1α/ARNT complex formation. Additionally, the activity of topoisomerase II α (TOPOII-α), one of the main regulators of DNA replication, results increased after its CK1δ-mediated phosphorylation on Ser-1106. Under stress conditions, CK1δ can interfere with DNA replication. In fact, CK1δ phosphorylates a main regulator of DNA methylation, the ubiquitin-like containing PHD and RING finger domains 1 protein (UHRF1), on Ser-108, increasing its proteasomal degradation.
The English, French, and generic name of the medication is spironolactone and this is its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, and JANTooltip Japanese Accepted Name. Its name is spironolactonum in Latin, Spironolacton in German, espironolactona in Spanish and Portuguese, and spironolattone in Italian (which is also its DCITTooltip Denominazione Comune Italiana). Spironolactone is also known by its developmental code names SC-9420 and NSC-150339.
=== 27 May === A spokeswoman for the German Defence Ministry confirmed that Ukraine had formally asked to be supplied with the Taurus KEPD 350 cruise missile. In Kharkiv Oblast, a woman was killed and another civilian was injured by Russian shelling in Kupiansk. Mikhail Vedernikov, Governor of Russia's Pskov Oblast, claimed that two drones struck an administrative building for a nearby oil pipeline, causing an explosion. No casualties were reported, however the building was damaged. The attack occurred less than ten kilometres from the Belarus border. In Kursk Oblast, a construction worker was reported to have been killed by Ukrainian shelling near the village of Plekhovo, a few kilometers from the international border. Another civilian, a security guard was killed by shelling in Shebekino, Belgorod Oblast. The Russian Defence Ministry claimed that its forces had intercepted two Storm Shadow missiles, 19 drones and several HIMARS and HARM missiles from Ukraine in the past 24 hours. The German Foreign Ministry confirmed that hundreds of its educational and cultural workers, including employees at the German school in Moscow and at the local branch of the Goethe Institute were to be expelled from Russia starting in June after it imposed a limit on the number of German employees in retaliation for the expulsion of Russian diplomats and staff from Germany.
Hydrogen peroxide (H2O2) is a nonplanar molecule with (twisted) C2 symmetry; this was first shown by Paul-Antoine Giguère in 1950 using infrared spectroscopy. Although the O−O bond is a single bond, the molecule has a relatively high energy barrier of 386 cm−1 (4.62 kJ/mol) for rotation between enantiomers via the anti configuration, and 2460 cm−1 (29.4 kJ/mol) via the eclipsed configuration. These barriers are proposed to be due to repulsion between the lone pairs of the adjacent oxygen atoms and dipolar effects between the two O–H bonds. For comparison, the rotational barrier for ethane is 1040 cm−1 (12.4 kJ/mol). The approximately 100° dihedral angle between the two O–H bonds makes the molecule chiral. It is the smallest and simplest molecule to exhibit enantiomerism. It has been proposed that the enantiospecific interactions of one rather than the other may have led to amplification of one enantiomeric form of ribonucleic acids and therefore an origin of homochirality in an RNA world. The molecular structures of gaseous and crystalline H2O2 are significantly different. This difference is attributed to the effects of hydrogen bonding, which is absent in the gaseous state. Crystals of H2O2 are tetragonal with the space group D44 or P41212.
Sources: en.wikipedia.org
Douglas Hart – bass (1984–1991) Murray Dalglish – drums (1984) Bobby Gillespie – drums (1984–1986, 2017) John Moore – rhythm guitar (1986–1987, 2012), drums (1985–1986) Martin Hewes – drums (1986) James Pinker – drums (1986) Dave Evans – rhythm guitar (1987–1989) Richard Thomas – drums (1988–1990) Ben Lurie – rhythm guitar, bass, organ (1989–1998) Steve Monti – drums (1990–1995) Matthew Parkin – bass (1992) Barry Blackler – drums (1992) Nick Sanderson – drums (1993–1998; died 2008) Lincoln Fong – bass (1994–1995) Geoff Donkin – drums (1998) Phil King – bass, rhythm guitar (1998, 2007–2015) Loz Colbert – drums (2007–2008) Brian Young – drums (2012–2021)
== Full list of explicitly revoked executive orders == This is a list of only the executive orders explicitly revoked under section two of Initial Rescissions of Harmful Executive Orders and Actions. Additionally, it does not include the 10 presidential memoranda also rescinded by the order, which were dated March 13, 2023, and January 3, 6, and 14, 2025.
=== Food packaging === A good food packaging material should be able to block out microbes (to prevent spoiling and foodborne illness) and prevent oxygen from entering (to prevent rancidity). Depending on the product, it may be also desirable to stop water vapor from going across (to maintain crispness or wetness), to block out light and ultraviolet, and/or be resistant to rough handling. Classical plastic-based materials satisfy these criteria, but they are not biodegradable and create a trash problem. Among biodegradable options, chitosan films and chitosan composite films come closest to fulfilling all of these goals. Chitosan also has an intrinsic antimicrobial activity, which could potentially provide an extra line of defense to microbes.
=== Run-flat tires === The introduction of run-flat tires and emergency spare tires by several tire and vehicle manufacturers has provided motivation to make at least some basic TPMS mandatory when using run-flat tires. With run-flat tires, the driver will most likely not notice that a tire is running flat, hence the so-called "run-flat warning systems" were introduced. These are most often first generation, purely roll-radius based iTPMS, which ensure that run-flat tires are not used beyond their limitations, usually 80 km/h (50 mph) and 80 km (50 miles) driving distance. The iTPMS market has progressed as well. Indirect TPMS are able to detect under-inflation through combined use of roll radius and spectrum analysis and hence four-wheel monitoring has become feasible. With this breakthrough, meeting the legal requirements is possible also with iTPMS.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.